Format

Send to

Choose Destination
Vaccine. 2010 Nov 10;28(48):7620-5. doi: 10.1016/j.vaccine.2010.09.053. Epub 2010 Sep 29.

Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds.

Author information

1
University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. kjs8@pitt.edu

Abstract

Influenza vaccination is now recommended for all ages; CDC pneumococcal polysaccharide vaccination (PPV) recommendations are comorbidity-based in nonelderly patients. We constructed a Markov model to estimate the cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-olds. Patients were followed for 10 years, with differing time horizons examined in sensitivity analyses. With 100% vaccine uptake, dual vaccination cost $37,700/QALY gained compared to a CDC recommendation strategy; with observed vaccine uptake, dual vaccination cost $5,300/QALY. Results were sensitive to shorter time horizons, favoring CDC recommendations. We found dual vaccination of all 50-year-olds economically reasonable. Shorter duration models may not fully account for PPV effectiveness.

PMID:
20887828
PMCID:
PMC2981678
DOI:
10.1016/j.vaccine.2010.09.053
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center